DE60109286D1 - Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn - Google Patents

Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn

Info

Publication number
DE60109286D1
DE60109286D1 DE60109286T DE60109286T DE60109286D1 DE 60109286 D1 DE60109286 D1 DE 60109286D1 DE 60109286 T DE60109286 T DE 60109286T DE 60109286 T DE60109286 T DE 60109286T DE 60109286 D1 DE60109286 D1 DE 60109286D1
Authority
DE
Germany
Prior art keywords
methoxychlor
pharmaceutical compositions
pharmaceutically acceptable
acceptable carrier
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60109286T
Other languages
English (en)
Other versions
DE60109286T2 (de
Inventor
Jordan L Holtzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE60109286D1 publication Critical patent/DE60109286D1/de
Application granted granted Critical
Publication of DE60109286T2 publication Critical patent/DE60109286T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Glass Compositions (AREA)
DE60109286T 2000-05-24 2001-05-23 Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn Expired - Lifetime DE60109286T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20685400P 2000-05-24 2000-05-24
US206854P 2000-05-24
PCT/US2001/016914 WO2001089500A2 (en) 2000-05-24 2001-05-23 Agents and methods for increasing brain chaperonin levels

Publications (2)

Publication Number Publication Date
DE60109286D1 true DE60109286D1 (de) 2005-04-14
DE60109286T2 DE60109286T2 (de) 2005-07-28

Family

ID=22768251

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60109286T Expired - Lifetime DE60109286T2 (de) 2000-05-24 2001-05-23 Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn

Country Status (13)

Country Link
US (2) US20030216480A1 (de)
EP (1) EP1289512B1 (de)
JP (1) JP4965048B2 (de)
AT (1) ATE290373T1 (de)
AU (2) AU2001263421B2 (de)
CA (1) CA2410395A1 (de)
DE (1) DE60109286T2 (de)
HK (1) HK1053987A1 (de)
IL (2) IL153058A0 (de)
MX (1) MXPA02011675A (de)
NO (1) NO330175B1 (de)
NZ (1) NZ522951A (de)
WO (1) WO2001089500A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750048B2 (en) * 2006-11-15 2010-07-06 Janssen Pharmaceutica Nv GPR40 agonists
KR101275264B1 (ko) * 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
WO2014012108A1 (en) * 2012-07-13 2014-01-16 Holtzman Jordan L Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
CN111505001A (zh) * 2020-06-12 2020-08-07 山东省医学科学院基础医学研究所 一种蛋白单磷酸尿苷酸化修饰的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2535000A (en) * 1949-04-29 1950-12-19 Moorman Mfg Company Insecticidal composition comprising ddt and methoxychlor
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CA1187409A (en) * 1983-02-09 1985-05-21 George S. Puritch Insecticide mixtures containing fatty acids
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP1649850A1 (de) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
IL136306A (en) * 1997-12-10 2005-09-25 Nps Pharma Inc Bis (fluorophenyl) alkylamides and related compounds, pharmaceutical compositions comprising them and their use in treating neurological disease or disorder
WO2000026251A2 (en) * 1998-10-30 2000-05-11 Holtzman Jordan L A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
MXPA01007486A (es) * 1999-01-25 2003-06-24 Optime Therapeutics Inc Formulaciones de liposomas.

Also Published As

Publication number Publication date
NO20025667D0 (no) 2002-11-25
NO20025667L (no) 2003-01-22
US20030216480A1 (en) 2003-11-20
AU6342101A (en) 2001-12-03
MXPA02011675A (es) 2004-07-30
WO2001089500A3 (en) 2002-04-25
IL153058A0 (en) 2003-06-24
JP4965048B2 (ja) 2012-07-04
NZ522951A (en) 2004-11-26
AU2001263421B2 (en) 2006-05-18
WO2001089500A2 (en) 2001-11-29
EP1289512A2 (de) 2003-03-12
DE60109286T2 (de) 2005-07-28
ATE290373T1 (de) 2005-03-15
JP2003535829A (ja) 2003-12-02
EP1289512B1 (de) 2005-03-09
IL153058A (en) 2010-05-31
HK1053987A1 (zh) 2003-11-14
US20100152303A1 (en) 2010-06-17
NO330175B1 (no) 2011-02-28
CA2410395A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
EA200400881A1 (ru) Азаарилпиперазины
DE69827651D1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
ATE259650T1 (de) Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
ATE283047T1 (de) Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
WO2001054681A8 (en) Composition for treatment of stress
DE3879873D1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE60109286D1 (de) Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
EP1323422B8 (de) Pharmazeutische Formulierung enhaltend Midazolam zur buccalen Verabreichung
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
NO20044698L (no) Statinterapi for a oke kognitiv opprettholdelse
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
ATE256474T1 (de) Hemmung der sichelbildung von erythrozyten mittels n-l-alpha-aspartyl-l-phenylalanine 1- methylester
CA2217463A1 (fr) Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels

Legal Events

Date Code Title Description
8364 No opposition during term of opposition